CAR T therapy is a personalized therapy that has become a recommended treatment option for certain hematologic cancers1-7
Prior to the introduction of CAR T therapy, patients who had relapsed or were unresponsive to treatment had limited treatment options and typically had a poor prognosis.8-10 Since the first approval in 2017, CAR T therapies have continued to evolve the treatment paradigm with 6 FDA approvals for over 10 indications.11-17 More oncologists have turned to CAR T therapies for their patients.18
53% of primary oncologists/hematologists have referred patients with various lymphoma types for CAR T therapy19*
Refer for CAR T consultation early to give your patients hope
*In preceding 6 months. Based on a 2021 US web-based survey of 371 oncologists.19
CAR T=chimeric antigen receptor T cell; FDA=Food and Drug Administration; NCCN=National Comprehensive Cancer Network.
NCCN makes no warranties of any kind whatsoever regarding their content, use, or application and disclaims any responsibility for their application or use in any way.
References
1. Albinger N, Hartmann J, Ullrich E. Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany. Gene Ther. 2021;28(9):513-527. 2. Nastoupil LJ, Jain MD, Feng L, et al. Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38(27):3119-3128. 3. Iacoboni G, Villacampa G, Martinez-Cibrian N, et al; GETH, GELTAMO Spanish Groups. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10(10):3214-3223. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for B-Cell Lymphomas V2.2023. © National Comprehensive Cancer Network, Inc. 2023. All rights reserved. Accessed February 8, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. 5. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 4, 2022. To view the most recent and complete version of the guideline, go online to NCCN.org. 6. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed March 16, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. 7. Lu J, Jiang G. The journey of CAR-T therapy in hematological malignancies. Mol Cancer. 2022;21(1):194. 8. Kumar S, Baizer L, Callander NS, et al. Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee. Blood Cancer J. 2022;12(6):98. 9. St-Pierre F, Gordon LI. CAR T-cell therapy for relapsed/refractory non-Hodgkin’s lymphoma: a comprehensive review. Clin Adv Hematol Oncol. 2022;20(5):309-318. 10. Greenbaum U, Mahadeo KM, Kebriaei P, Shpall EJ, Saini NY. Chimeric antigen receptor T-cells in B-acute lymphoblastic leukemia: state of the art and future directions. Front Oncol. 2020;10:1594. 11. Zhang X, Zhu L, Zhang H, Chen S, Xiao Y. CAR-T cell therapy in hematological malignancies: current opportunities and challenges. Front Immunol. 2022;13:927153. 12. National Library of Medicine. Updated May 27, 2022. Accessed February 4, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aad3ba54-dfd3-4cb3-9e2b-c5ef89559189 13. National Library of Medicine. Updated November 9, 2022. Accessed February 4, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9b70606e-b99c-4272-a0f1-b5523cce0c59 14. National Library of Medicine. Updated September 19, 2022. Accessed February 4, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a16108c2-7ca7-45af-965e-54bda4713022 15. National Library of Medicine. Updated July 29, 2022. Accessed February 4, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=594bb413-af3b-4b97-afb3-bfe2b174f2ed 16. National Library of Medicine. Updated October 13, 2022. Accessed February 4, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b90c1fe7-f5cc-464e-958a-af36e9c26d7c 17. National Library of Medicine. Updated March 9, 2022. Accessed February 4, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d040b91-3fb8-41db-ba7f-60a36f06e2c2 18. Gajra A, Jeune-Smith Y, Kish J, Yeh T-C, Hime S, Feinberg BA. Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy. 2020;12(10):725-732. 19. Gajra A, Jeune-Smith Y, Feinberg BA. Barriers to referral for chimeric antigen receptor T cell (CAR-T) therapies among U.S. community hematologists/oncologists (cH/O). Blood. 2021;138(suppl 1):4010-4011.